Baxdrostat
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 100 publications
Pharmacokinetics of novel drugs for the treatment of Diabetic nephropathy.
Journal: Expert opinion on drug metabolism & toxicology
Published: September 08, 2026
Efficacy and Safety of Baxdrostat in Hypertension: A GRADE-Assessed Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Journal: The Annals of pharmacotherapy
Published: September 07, 2026
Efficacy and Safety of Baxdrostat for Patients With Uncontrolled or Resistant Hypertension: A Systematic Review and Meta-Analysis.
Journal: Cardiology in review
Published: August 13, 2026
Efficacy and Safety of Selective Aldosterone Synthase Inhibitors in Uncontrolled Hypertension: A Systematic Review and Dose-Specific Network Meta-Analysis of Randomized Controlled Trials.
Journal: Cardiology in review
Published: July 31, 2026
Baxdrostat and selective aldosterone synthase inhibition in hard-to-control hypertension: mechanism, evidence, safety, and future clinical positioning.
Journal: Expert opinion on pharmacotherapy
Published: July 17, 2026
Targeting Aldosterone Biosynthesis in Uncontrolled and Resistant Hypertension: A Systematic Review and Meta-Analysis of Randomized Trials of Lorundrostat and Baxdrostat.
Journal: Journal of cardiovascular pharmacology and therapeutics
Published: July 13, 2026
Effect of fourth-line antihypertensive therapy on clinic systolic blood pressure in resistant hypertension: a systematic review and meta-analysis.
Journal: Blood pressure
Published: June 29, 2026
Baxdrostat (Baxfendy) - an aldosterone synthase inhibitor for hypertension.
Journal: The Medical letter on drugs and therapeutics
Published: June 25, 2026
Can baxdrostat redefine blood pressure control in resistant and uncontrolled hypertension? a systematic review, meta-analysis, and trial sequential analysis.
Journal: Naunyn-Schmiedeberg's archives of pharmacology
Published: June 04, 2026
Dose-response efficacy and safety of the aldosterone synthase inhibitor baxdrostat in resistant hypertension: a systematic review and network meta-analysis.
Journal: Naunyn-Schmiedeberg's archives of pharmacology
Published: May 26, 2026
Combined Aldosterone Synthase and SGLT2 Inhibition: A Recipe for Success in CKD with Uncontrolled Blood Pressure?
Journal: Current hypertension reports
Published: May 15, 2026
Last Updated: 09/26/2026